Novel Candidates for the Drug Treatment of Alzheimer’s Disease
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Medicinal Chemistry".
Deadline for manuscript submissions: closed (30 November 2023) | Viewed by 709
Special Issue Editors
Interests: Functional genomics and drug designing
2. Department of Medical Sciences, University of Aveiro, 3810-193 Aveiro, Portugal
Interests: biomaterials; chromium compounds; pollutants; obesogen; natural compounds
Special Issues, Collections and Topics in MDPI journals
Interests: molecular toxicology; drug design and development
Special Issue Information
Dear Colleagues,
Alzheimer’s disease (AD) is irreversible and the most common neurodegenerative disease worldwide, which is identified by senile dementia, characterized by progressive memory and neuronal loss, combined with cognitive impairment. There is no permanent cure available for AD. The primary aim of most of the therapeutic strategies for AD is to improve the quality of daily life of the patients, especially targeting their memory, eenhancing their independence. These therapeutics work either by easing the symptoms or by slowing down the progression of the disease. Not all patients respond to the drugs in a similar manner and often, they do not respond to the drugs at all. In such cases, inventing new therapeutic molecules as well as drug repurposing become crucial to treat such patients. In order to identify and evaluate new treatments for AD, it will be critical to utilise more rigorous, evidence-based approaches of drug development and clinical trials, ensuring the mechanisms of action are confirmed, and trial designs are optimised. Hence, in line with the latest developments in therapeutic research on AD, we invite research, review and correspondence articles on novel approaches/molecules/therapeutic strategies for the treatment of Alzheimer’s disease.
Dr. Himanshu Narayan Singh
Prof. Dr. Maria de Lourdes Pereira
Prof. Dr. Bechan Sharma
Dr. Vishnu Swarup
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Alzheimer’s disease
- immunotherapy
- drug delivery
- amyloid beta
- cholinesterase inhibitors
- novel therapeutics
